Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05164094 · ClinicalTrials.gov registry record · Phase 1
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
A Phase 1 study of Epstein-Barr Virus Infection, sponsored by ModernaTX.
- Active
- Registry status
- Phase 1
- Development phase
- 867
- Enrollment target
- 20
- Study locations
NCT05164094: Active Phase 1 study of Epstein-Barr Virus Infection, sponsored by ModernaTX.
NCT05164094 is a Phase 1 study of Epstein-Barr Virus Infection that is active but no longer recruiting, run by ModernaTX. The registered enrollment target is 867 participants, above the 340-participant average among 6 other Epstein-Barr Virus Infection trials with a reported enrollment target (155% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05164094, a Phase 1 study of Epstein-Barr Virus Infection, is active but no longer recruiting, sponsored by ModernaTX.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 867 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults, the main objective of Part B is to evaluate the safety and reactogenicity of mRNA-1189 in 12- to \<18-year-old healthy EBV-seronegative adolescents, and the main objective of Part C is to evaluate the safety and reactogenicity of mRNA-1189 in 10- to 21-year-old healthy adolescents and adults.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL mRNA-1189
Study Locations (20)
California
- Smart Cures Clinical Research - Anaheim
- Benchmark Research - Colton - HyperCore - PPDS - Colton
- Fomat Medical Research - Oxnard
- Center For Clinical Trials LLC -Paramount - Paramount
- Artemis Institute For Clinical Research LLC - Riverside - Headlands - PPDS - Riverside
- Peninsula Research Associates - Headlands Research - PPDS - Rolling Hills
- Velocity Clinical Research - Banning - PPDS - San Bernardino
- Acclaim Clinical Research - San Diego
- California Research Foundation - 4180 Ruffin Rd - San Diego
- Orange County Research Center - Tustin
Georgia
- iResearch Savannah - CenExel - PPDS - Savannah
- Meridian Clinical Research-(Savannah Georgia) - Platinum - PPDS - Savannah
- Clinical Research Atlanta - Headlands - PPDS - Stockbridge
Florida
- Research Centers of America - ERG - Hollywood
- Jacksonville Center For Clinical Research - ERN - PPDS - Jacksonville
Illinois
- Olivo Medical and Wellness Center - Chicago
- DM Clinical Research - River Forest
Alabama
- Medical Affiliated Research Institute - Huntsville
Arizona
- Alliance for Multispecialty Research, LLC - Tempe
Idaho
- Velocity Clinical Research - Meridian
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 867 participants |
| Start Date | 2021-12-28 |
| Est. Completion | 2026-10-05 |
| Phase | Phase 1 |
What the registry record for NCT05164094 still lists
NCT05164094 is an interventional study that assigns participants to a tested intervention. The registered 867 participants enrollment target is mid-sized for trials with a published cap, above the 340-participant average among 6 other Epstein-Barr Virus Infection trials with a reported enrollment target (155% higher).
The record links to 1 condition, with Epstein-Barr Virus Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05164094 names 20 study sites across 7 states, led by California, Georgia, Florida.
Frequently Asked Questions
What is clinical trial NCT05164094 about?
NCT05164094 is a clinical study titled "A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults". The main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults, the main objective of Part B is to evaluate the safety and reactogenicity of mRNA-1189 in 12- to \<18-year-old healthy EBV-seronegative adolescents, and the main...
What is the current status of trial NCT05164094?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 867 participants. The study started on 2021-12-28. Estimated completion is 2026-10-05.
What conditions does trial NCT05164094 study?
This clinical trial studies the following conditions: Epstein-Barr Virus Infection.
What interventions are being tested in trial NCT05164094?
The interventions under investigation include: Placebo (BIOLOGICAL), mRNA-1189 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05164094?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05164094 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epstein-Barr Virus Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection
RECRUITING · Phase 1
-
Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons
ACTIVE NOT RECRUITING · Phase 1
-
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection
ACTIVE NOT RECRUITING · Phase 1
-
Administration of Donor T Cells With the Caspase-9 Suicide Gene
ACTIVE NOT RECRUITING · Phase 1
-
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04933552 · 867 participants
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
- NCT06077760 · 868 participants · Phase 3
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
- NCT06822790 · 869 participants · Phase 3
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
- NCT05369052 · 865 participants · Phase 3
Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI